Amgen presented five-year Phase II data in episodic migraines at the Migraine Trust Virtual Symposium showing that the anti-CGRP medication Aimovig helped patients achieve sustained reductions in monthly migraine days.

AbbVie’s investigational migraine drug atogepant significantly reduced mean monthly migraine days across a 12-week course of treatment.

The Food and Drug Administration approved an autoinjector device for Teva Pharmaceuticals USA Inc.’s Ajovy (fremanezumab-vfrm) injection.

Teva Pharmaceutical Industries Ltd.’s anti-CGRP drug fremanezumab hit the target reducing monthly migraine days in a late-stage study.